High Growth Tech Stocks To Watch In December 2024

In This Article:

Over the last 7 days, the U.S. market has risen 1.1%, and over the past 12 months, it is up by an impressive 32%, with earnings forecasted to grow by 16% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and expanding market opportunities.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

★★★★★★

Ardelyx

25.47%

69.63%

★★★★★★

Sarepta Therapeutics

24.00%

42.51%

★★★★★★

Alnylam Pharmaceuticals

22.35%

70.33%

★★★★★★

Clene

78.50%

60.16%

★★★★★★

TG Therapeutics

34.66%

56.98%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 242 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Arcutis Biotherapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Arcutis Biotherapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for dermatological diseases, with a market cap of $1.48 billion.

Operations: Arcutis Biotherapeutics focuses on developing and commercializing pharmaceutical treatments for dermatological diseases, generating revenue primarily from its pharmaceuticals segment, which amounts to $138.71 million.

Arcutis Biotherapeutics is navigating a transformative phase with strategic executive promotions poised to enhance its ZORYVE portfolio's market reach. The recent approval of ZORYVE foam in Canada underscores Arcutis's commitment to expanding its dermatological treatments, leveraging the drug's efficacy in reducing symptoms of seborrheic dermatitis. Financially, the company reported a significant revenue jump to $125.18 million over nine months, up from $46.08 million year-over-year, reflecting a robust 34.8% growth rate that outpaces broader market trends. Despite these advances, challenges remain as evidenced by a net loss reduction to $129.25 million from $195.86 million and ongoing unprofitability forecasts for the next three years; however, earnings are expected to surge by approximately 72.4% annually as profitability nears.

NasdaqGS:ARQT Earnings and Revenue Growth as at Dec 2024
NasdaqGS:ARQT Earnings and Revenue Growth as at Dec 2024

BioCryst Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing oral small-molecule and protein therapeutics for the treatment of rare diseases, with a market cap of $1.52 billion.